bulevirtide HDV
Selected indexed studies
- Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial. (J Hepatol, 2024) [PMID:38734383]
- Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies. (J Hepatol, 2024) [PMID:38340811]
- Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D. (N Engl J Med, 2024) [PMID:38842520]
_Worker-drafted node — pending editorial review._
Connections
bulevirtide HDV is a side effect of
Sources
- Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial. (2024) pubmed
- Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies. (2024) pubmed
- Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D. (2024) pubmed
- A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D. (2023) pubmed
- Hepatitis D: A Review. (2023) pubmed
- Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide. (2024) pubmed
- Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis. (2025) pubmed
- Bulevirtide for HBV and HDV infections. (2021) pubmed
- Bulevirtide: First Approval. (2020) pubmed
- Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV. (2025) pubmed